PD distributes a range of branded, generic prescription medicines and over-the-counter (OTC) products in SA as well as other key markets across the African continent.
PD is amongst the fastest growing top 20 pharmaceutical companies in SA and the 3rd largest generic company in the SA prescriptions market.
PD is the biggest supplier of cardiovascular pharmaceuticals in SA, and also manufactures products to address therapies such as central nervous system (CNS), gastrointestinal, diabetes and gynecological and male health segments. In 2013, PD also entered the SA anti-infective market, supplying IV antibiotics to hospitals. Its OTC products portfolio includes antihistamines, cold & flu medication and heartburn treatment.
On the acquisition, CEO of PD, Paul Anley, said: “Lupin has been an extremely strong partner in our business since 2008 and we have always had an excellent relationship.”
“The fact that Lupin has increased its shareholding in PD is a huge compliment and augers very well for our continued success,” continued Anley.
CEO of Lupin Limited, Vinita Gupta, added: “We are delighted with this development as Africa is fast emerging as one of the growth engines of the future. We deeply appreciate the efforts of Paul Anley in building PD into a very robust and the fastest growth pharma major in South Africa. We are very pleased that Paul Anley has agreed to continue as the CEO.”